Drug Interactions between Fyarro and sirolimus
This report displays the potential drug interactions for the following 2 drugs:
- Fyarro (sirolimus protein-bound)
- sirolimus
Interactions between your drugs
No interactions were found between Fyarro and sirolimus. However, this does not necessarily mean no interactions exist. Always consult your healthcare provider.
Fyarro
A total of 408 drugs are known to interact with Fyarro.
- Fyarro is in the drug class mTOR inhibitors.
- Fyarro is used to treat Malignant Perivascular Epithelioid Cell Tumor.
sirolimus
A total of 716 drugs are known to interact with sirolimus.
- Sirolimus is in the following drug classes: mTOR inhibitors, selective immunosuppressants.
- Sirolimus is used to treat the following conditions:
Drug and food interactions
sirolimus food
Applies to: sirolimus
ADJUST DOSING INTERVAL: Consumption of food can decrease the rate and extent of gastrointestinal absorption of sirolimus. Also, the consumption of grapefruit juice may result in increased sirolimus trough concentrations.
MANAGEMENT: Experts recommend that this drug be taken either at least one hour prior to eating or consistently with or without food to avoid variations in sirolimus blood levels. The manufacturer recommends against using grapefruit juice for dilution of sirolimus doses. Patients should be monitored for clinical and laboratory evidence of altered immunosuppressant effects.
References (1)
- (2001) "Product Information. Rapamune (sirolimus)." Wyeth-Ayerst Laboratories
sirolimus protein-bound food
Applies to: Fyarro (sirolimus protein-bound)
GENERALLY AVOID: Coadministration of protein-bound sirolimus intravenous suspension with grapefruit juice may increase the systemic exposure to sirolimus. The proposed mechanism is inhibition of CYP450 3A4-mediated metabolism of sirolimus by certain compounds present in grapefruit. However, grapefruit juice primarily inhibits CYP450 3A4-mediated first-pass metabolism in the gut wall and may have limited effects on medications that are not administered orally. No formal studies evaluating the drug interaction potential of protein-bound sirolimus have been conducted. In general, the effect of grapefruit juice is concentration-, dose- and preparation-dependent, and can vary widely among brands. Certain preparations of grapefruit juice (e.g., high dose, double strength) have sometimes demonstrated potent inhibition of CYP450 3A4, while other preparations (e.g., low dose, single strength) have typically demonstrated moderate inhibition.
MANAGEMENT: The manufacturer recommends avoiding grapefruit and grapefruit juice during treatment with protein-bound sirolimus.
References (1)
- (2022) "Product Information. Fyarro (sirolimus protein-bound)." Aadi Bioscience, Inc.
Therapeutic duplication warnings
Therapeutic duplication is the use of more than one medicine from the same drug category or therapeutic class to treat the same condition. This can be intentional in cases where drugs with similar actions are used together for demonstrated therapeutic benefit. It can also be unintentional in cases where a patient has been treated by more than one doctor, or had prescriptions filled at more than one pharmacy, and can have potentially adverse consequences.
Macrolide immunosuppressants
Therapeutic duplication
The recommended maximum number of medicines in the 'macrolide immunosuppressants' category to be taken concurrently is usually one. Your list includes two medicines belonging to the 'macrolide immunosuppressants' category:
- Fyarro (sirolimus protein-bound)
- sirolimus
Note: In certain circumstances, the benefits of taking this combination of drugs may outweigh any risks. Always consult your healthcare provider before making changes to your medications or dosage.
Mtor inhibitors
Therapeutic duplication
The recommended maximum number of medicines in the 'mTOR inhibitors' category to be taken concurrently is usually one. Your list includes two medicines belonging to the 'mTOR inhibitors' category:
- Fyarro (sirolimus protein-bound)
- sirolimus
Note: In certain circumstances, the benefits of taking this combination of drugs may outweigh any risks. Always consult your healthcare provider before making changes to your medications or dosage.
See also
Drug Interaction Classification
Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit. | |
Moderately clinically significant. Usually avoid combinations; use it only under special circumstances. | |
Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan. | |
No interaction information available. |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
Check Interactions
To view an interaction report containing 4 (or more) medications, please sign in or create an account.
Save Interactions List
Sign in to your account to save this drug interaction list.